PRF1 and neoplasm: Through genetic modification of T cells in the peripheral blood of patients or donors, this therapy enables T cells to bind and activate specific antigens on the surface of tumor cells, and directly kill tumor cells by releasing perforin, clindamycin B, etc. [11].